C hemically induced tumors in animals possess tumorspecific antigens (TSA), 1 as demonstrated by the ability of animals transplanted with a syngeneic tumor to reject a second challenge of the same tumor (1) (2) (3) . The relevance of these observations to human neoplasia has been questioned, since spontaneously arising tumors in mice are essentially nonimmunogenic, suggesting that the existence of highly immunogenic tumors in nature is quite rare (4) . While it now appears that at least some spontaneous tumors can be recognized by the immune system, even these elicit a weak immune response of little or no protective value (5) . In several instances, however, weak anti-tumor responses generated in animals bearing "nonimmunogenic" tumors could be potentiated, protecting the animal from a subsequent tumor challenge (5-7) . The growth of some tumors in experimental animals, as well as in human patients, is often associated with the establishment of an active state of immune suppression (8) (9) (10) . Studies by North and co-workers using chemically induced tumors in mice similar to the tumor system used in our studies, have shown that tumor progression in the 1217 animal induced a population of Lyt-1+2 -T cells that suppressed the emerging anti-tumor response mediated by Lyt-1 -2+ T cells (10) .
IL-2 is a growth factor that stimulates the proliferation of cytotoxic T cells (11), helper T cells (12), NK cells (13), and LAK cells (14), all of which can participate in the anti-tumor response. In the mouse, systemic administration of IL-2 induces the expansion and long-term persistence of adoptively transferred tumor-specific T cells (15-18) . To test whether "locally" secreted cytokines were able to influence the generation of anti-tumor immune responses we used retroviral vectors to introduce the gene for human IL-2 into CMS-5 cells. CMS-5, a methylcholanthrene-induced tumor in BALB/c mice, is a weakly immunogenic tumor devoid of viral antigens (19, 20) . The effect of varying levels of cytokine expression on tumor growth in vivo and on the generation of a cellular immune response was then measured .
Our results demonstrated that local secretion of IL-2 abrogated the tumorigenicity of the cytokine-producing CMS-5 cells and induced a long-lasting protective immune response against a subsequent tumor graft . The IL-2-producing tumor cells abrogated growth of co-injected tumor cells that were not transfected with cytokine genes and induced a long-lasting state of T cell immunity as measured by persistence of a specific cytotoxic activity. These results suggest that modification of tumor cells with cytokine genes is a potentially useful strategy to manipulate the host mediated anti-tumor immune response .
Materials and Methods
Retroviral Vector Design and Infection of Tumor Cells. A 528-bp long DNA fragment encoding the human IL2 cDNA was obtained from the plasmid PBCII/RSV/AT (21) by digestion with restriction enzymes BamHI and HindIIl. A 852-by-long DNA fragment encoding the HSV thymidine kinase (TK) promoter was obtained from plasmid PHSV106 (22) by digestion with restriction enzymes BamHI and BglII. A 794-by-long DNA fragment encoding the major immediate early human CMV promoter was obtained from plasmid PRR23 (23) by digestion with restriction enzymes Ball and SmaI . N2 is a retroviral vector derived from the genome of Moloney murine leukemia virus (MLV), containing the bacterial neomycin resistance (neo) gene which is used as a selectable marker (24) . A schematic diagram presenting the various vector constructs used in these studies is shown in Fig. 1 . Vector N2/1L2 was constructed by cloning the IL-2 cDNA into a unique Bc1I site present upstream from the initiation codon of the neo gene generating a bicistronic transcriptional unit . The TK and CMV promoter encoding DNA fragments were fused to the IL2 cDNA fragments and cloned into a unique Xhol site present downstream to the neo gene coding sequences to generate vector constructs N2/TKIL2 and N2/CMVIL2. The TKIL2 fusion product was cloned into the SnaBI site present in the polylinker in the 3' LTR of a modified N2 vector as described by Hantzopoulos et al . (25) , to generate vector constructs DC/TKIL2 . The prefix DC is short for Double Copy to describe this vector design in which the foreign gene is inserted into the 3' LTR of retroviral vector. For more details on DC vectors, see Hantzopoulos et al . (25) . DCA is a previously described vector in which the human ADA minigene was cloned into the 3' LTR of the N2 vector (25) . Retroviral vector constructs were converted to corresponding virus using established procedures. Briefly, vector DNA was transfected into a helper-free, ecotropic (N2/IL2, N2/TKIL2, N2/CMVIL2, and DC/TKIL2) or amphotropic (DCA) packaging cell line (26, 27) . Colonies were isolated by G418 selection, expanded to cell lines, and cell-free supernatant was tested for the presence of virus. Cell lines secreting high titer of virus (106-105/Neo CFU/ml) were used to infect CMS-5 cells. Clonal derivates of CMS-5 cells were isolated by G418 selection, expanded to cell lines, and secretion of IL2 into the cell supernatant was measured . Absence of replication-competent virus in the cytokine-producing CMS-5 cells was shown by the inability to transfer G418 resistance to NIH 3T3 cells.
Human 11,2 Assay. Supernatant from 2 x 106 semiconfluent unmodified or 11,2 secreting CMS-5 cells was collected after 48 h and assayed for human IL-2 . IL2 activity was measured using IL2-dependent human primary lymphoblasts in a proliferation assay as previously described (28) , and results were confirmed by ELISA (Genzyme, Boston, MA). DMS-1, a specific mAb to human 11,2 (29), was used to inhibit IL2 activity.
Tumor Cell Lines and Animal Studies. CMS-5 is a methylcholanthrene-induced fibrosarcoma of BALB/c origin, shown to be devoid of viral antigens (19) and weakly immunogenic when compared with CMS-13 or Meth A, two noncrossreacting methylcholanthrene-induced tumors of the same genetic background (Srivastava, P., personal communication; reference 20) . CMS-5, 1218 CMS-13, and Meth A were adapted to culture and grown in DMEM medium supplemented with 10% FCS. BALB/c mice were obtained from a colony bred at Sloan-Kettering Institute, from which CMS-5, CMS-13, and Meth A tumors originated . Tumor cell injections were carried out using freshly prepared tumor cells that were removed from theculture plates by trypsinization and washed twice in PBS. Cells were injected intradermally in the dorsal root of the animal. Tumor growth was measured in millimeters using a caliper and was recorded as mean diameter (longest surface length (a) and width (b), (a + b) :2).
"Cr-release Assay. Cytotoxicity of spleen cells from tumorbearing and tumor-free BALB/c mice was assayed on different target cells in an 18-h "Cr-release assay and carried out in U-bottomed, 96-well microtiter plates . CTL were generated by culturing in vivo immunized spleen cells for 6 d at a concentration of 106 cells/ml in RPMI medium, 10% FCS, penicillin, streptomycin, and 2 mM L-glutamine, together with 2.5 x 104 irradiated (6,000 rad) CMS-5 stimulator cells/ml. Cultures were harvested on day 6. Target cells were prepared by culturing cells for 1 h in the presence of 250 ACi of "Cr sodium chromate, washed twice, and counted. 10 4 labeled target cells per well were mixed with effector lymphocytes to yield several E/T cell ratios and were incubated for 18 h. Percent specific lysis was calculated as : 100 x [(cpm experimental wells -cpm . spontaneous release)/(cpm maximum release -cpm spontaneous release)]. Spontaneous release of all targets was <25% . 
Results
Generation of Tumor Cell Lines Expressing IL2. Fig. 1 shows the retroviral vector constructs that were used to introduce and express the human IL-2 gene in tumor cells. The retroviral vectors used in this study were derived from MLV and are based on the high titer N2 retroviral vector, which also contains the bacterial neomycin resistance (neo) selectable gene (24) . For additional details see Materials and Methods. Vector DNA was converted to corresponding virus using established procedures . Briefly, vector DNA was transfected into a packaging cell line, and neomycin resistant colonies were selected with G418. Drug-resistant colonies were isolated and expanded to cell lines. Virus-containing cell-free supernatant was used to infect CMS-5 cells and clones were isolated. DNA blot analysis of G418-resistant CMS-5 cells was used to show that an intact provirus was present in the infected cells (data not shown) .
Expression of the IL2 gene in the CMS-5 cells transduced with the retroviral vectors was determined by measuring the secretion of the cytokine into the cell supernatant first using a bioassay and then confirming these results with an ELISA test ( Table 1) . Clonal isolates of CMS-5 cells were found to vary in their expression and secretion of IL2 depending on the particular retroviral vector used (Table 1) . In each case, human IL2 activity could be neutralized by an appropriate mAb (data not shown). Secretion of human IL2 had no discernible effect on cell morphology or on the growth rate in culture compared with parental CMS-5 cells or CMS-5 cells (Table 2) . Thus, localized IL2 secretion altered the ability of CMS-5 cells to cause tumors in vivo .
In Vivo Immune Response Generated by Cytokineproducing CMS-5 Cells. An association between cytokine secretion and growth of modified tumor cells, such as we observed, could be a result of altered growth properties of the tumor cells following the genetic manipulation they underwent or ofan immune response triggered by the cytokines . We excluded the first possibility, since our results showed no change on cell morphology, viability, or growth rate in culture of vector modified tumor cells compared with parental CMS-5 cells (data not shown) . To test the more intriguing possibility that increased amounts of cytokine secretion played a role in the reduced outgrowth of tumor cells an experiment was performed in which 106 N2/IL2/CMS5 cells were mixed with increasing numbers of unmodified tumor cells and injected into mice. Our results indicated that co-injection of 106 1172-producing cells was able to induce the rejection of up to 8 x 10 5 unmodified tumor cells (Fig. 3) . Although 1 .6 x 106 tumor cells were not rejected, the growth of the resulting tumor was considerably reduced . In fact, injection of 2 x 105 unmodified tumor cells alone generated a larger tumor than injection of 1 .6 x 106 tumor cells mixed with the IL2-producing cells . These observations demonstrated that local secretion of IL2 influenced the growth of unmodified tumor cells and were consistent with the hypothesis that an immune response was induced that was responsible for the loss of tumorigenicity of CMS-5 cells .
Further support for this hypothesis was obtained when mice that had rejected an 1172-producing CMS-5 tumor were Table 2 . Tumorigenic Potential of Parental and Cytokineproducing CMS-5 Cells E E fA 0 " Growing slowly and regressing after several weeks . challenged after 6 wk with 2 x 10 5 CMS-5 cells, a number that usually causes tumor formation . All mice failed to show tumors at the site of the challenge (Table 3) . Furthermore, Meth A and CMS-13, two noncrossreactive methylcholan- trene-induced fibrosarcomas of the same genetic background, were not rejected (data not shown) . Both of these cell lines had been grown in vitro in a fashion identical to CMS-5 cells, thereby also eliminating the possibility that rejection of CMS-5 cells was due to sensitization to serum proteins. Since all control mice developed tumors, protection was specific. Thus, the abrogation of tumorigenicity was characterized by a process that was CMS-5 specific, had memory, and was best explained by the existence of a protective immune response against the parental tumor.
In Vitro Lytic Activity ofSpleen Cells Derived from Animals Injected with Parental and Cytokineproducing CMS-5 Cells. Next we tested whether a CTL response might be at least partially responsible for the failure of IIr2-producing tumor cells to grow. Since we reasoned that an ongoing anti-tumor immune response would best be detectable in animals exhibiting reduced tumor growth, spleens were taken from mice that had been inoculated with IL2-producing tumor cells that grew at a significantly reduced rate, or from mice injected with unmodified CMS-5 cells. The nonadherent T cell-enriched populations were then cocultured in vitro with irradiated, parental CMS-5 cells for 6 d and tested in a standard "Crrelease assay for their ability to lyse various targets including parental CMS-5 cells, an IL2-producing CMS-5 line (N2/IL2/CMS5), K562, an NK-sensitive cell line, and CMS-13, a methylcholanthrene induced noncrossreactive BALB/c fibrosarcoma (20) .
Our results indicated that mice injected with unmodified CMS-5 cells were able to lyse parental CMS-5 cells and IL-2-producing CMS-5 cells, if effector spleen cells were taken at day 11 after injection of tumor cells (Fig. 4, upper left) . Neither K562 nor CMS13 cells were lysed . In other experiments, YAC-1 cells, another NK sensitive cell line, were also shown to be resistant to lysis by the activated spleen cells (data not shown) . On the other hand, if spleen cells were taken from mice inoculated with the unmodified tumor 28 d after the injection of CMS-5 cells, there was no longer detectable lysis of unmodified CMS-5 cells (Fig. 4, upper right) . This observation is consistent with the transient nature of the CTL response against CMS-5 and several other mouse 1221 Gansbacher et al . tumors, which is followed by the emergence of a state of immune suppression mediated by a population of tumor-specific T suppressor cells (10, 30, 31) . In contrast, spleen cells derived as late as 75 d after injection of IL2-producing CMS-5 cells still demonstrated a strong CTL response, similar to that observed with spleen cells taken 11 d after injection of unmodified CMS-5 cells (Fig. 4 , lower left and lower right) . Thus, the normal transient CTL response was not seen in the mice injected with IL-2-secreting tumors, but rather was replaced by one that was long lived . We attempted to investigate in vitro whether secretion of IL-2 by the tumor cells could influence T cell activity by testing the ability of parental CMS-5 cells and their IL-2-producing counterparts to serve as targets for CTL . Effector cells were produced by inoculating mice with parental CMS-5 cells. After 18 d spleen cells were isolated, stimulated in vitro for 6 d with irradiated unmodified CMS-5 cells, and used as effectors in a CML assay against a panel of targets . As expected, given the immune suppression in mice inoculated with tumor cells close to 3 wk before the harvest of spleen cells (10) , only low levels of lysis was observed when unmodified CMS-5 cells were used as targets (Fig. 5) . In contrast, efficient lysis was observed when 11,2-producing CMS-5 cells were used as targets (Figs . 4 and 5) . Moreover, the efficiency of lysis Table 1 ). Even parental CMS-5 cells could be made susceptible to lysis by the addition of exogenous 11,2 during the 18 h of incubation with the activated CTL . It is estimated that 1-3 U/ml of IL2 accumulate during the lysis reaction when 10,000 N2/IL2 vector-containing CMS-5 cells are used as targets, while 30 U/ml of exogenous IL2 were used in the experiment shown in Fig . 5 . In other experiments (data not shown), 5 and 2 U/ml of exogenous IL2 were effective at inducing lysis of CMS-5 cells, indicating that IL2 secretion from the tumor cells could indeed be responsible for the increase in lysis seen . Additional support was obtained in experiments in which the addition of an anti-IL2, but not control, mAb to the overnight CML reaction inhibited the lysis of N2/IL-2/CMS-5 target cells by -50% (data not shown) . The possibility that the secreted 11,2 was responsible for the increased target cell destruction by reducing the viability of the target cells during the 18-h incubation period was excluded, since there was no lysis by lymphocytes that were taken directly from parental CMS-5 tumor-bearing mice and exposed to IL-2-secreting target cells without a 6-d period of cocultivation (data not shown) .
Systemic administration of cytokines into experimental animals is used with increased frequency to probe the functions of the immune system and to enhance the immunotherapeutic value of treatments for viral diseases and cancer. Transfer of cytokine genes into tumor cells approximates more closely the physiological mode of cytokine secretion in the course of an immune response, because it leads to the highly localized secretion of low levels of cytokines which ceases with the regression of the tumor. Retroviral gene transfer is a highly efficient method to introduce genes into mammalian cells, resulting in integration of cytokine genes into the cell chromosome and persistent expression of low levels of cytokine.
In this study retroviral vectors were used to introduce and express the 11,2 gene in CMS-5 cells (Table 1) .
Though we estimated that <50-400 U of IL2 were secreted from the tumor cells injected in the back of the mouse (assuming that the injected tumor cells increase in number -10-fold and persist in the mouse for 1 wk before complete regression), our results demonstrated that the modification ofweakly immunogenic tumor cells to secrete 11,2 effectively abrogated their ability to form tumors in mice (Fig . 2 and Table 2 Abrogation of tumorigenicity of parental CMS-5 cells admixed with IL2-producing counterparts suggests that the inhibition was host mediated (Fig. 3) . Rejection of 8 x 105 tumor cells and significant inhibition of growth of 1 .6 x 10 6 tumor cells admixed with IL2 producers attested to the potency of the protective effect resulting from localized secretion of IL2 in the vicinity of the emerging tumor. This was confirmed in the experiment described in Table 3 which shows that mice immunized with IL-2-producing tumor cells developed a specific and long-lasting immune response since they are fully protected from a challenge with a highly tumorigenic dose of CMS-5 cells . The ability to induce protective immunity using IL2-producing tumor cells compares favorably with previous reports that have shown that BALB/c mice can be immunized against CMS-5 cells by two injections of 2 .5 x 107 irradiated CMS-5 cells . The highest tumor challenge that could be rejected using this protocol was 75,000 CMS-5 cells (20) .
The emergence of a protective immune response against the parental tumor cells correlated with the appearance of tumor-specific cytotoxic T cells in spleens derived from mice injected with IL2-producing CMS-5 cells, implicating this effector arm of the immune system in their eradication (Fig .  4) . Persistence of a long-lasting immune response (Table 3) and CTL activity in the spleens of mice injected with IL-2-producing cells, but not in the spleens of mice injected with the parental CMS-5 cells (Fig. 4) , suggested that secretion of IL2 from the tumor cells led to the induction of a long-lasting state of T cell immunity.
As shown in Fig. 5 (and Fig. 4 , upper right), IL-2-secreting CMS-5 cells, but not unmodified CMS-5 cells, were efficiently and specifically lysed by spleen cells taken from mice injected with unmodified CMS-5 cells at a time point when the animals were usually immunosuppressed, raising the possibility that (a) IL2 secretion by the tumor cells makes it possible to circumvent an existing state of suppression and (b) in the spleen of an immunosuppressed tumor bearing animal, the suppressor cells coexist with primed CTL. These results can be also interpreted to suggest that a weak anti-tumor immune response induces T cell anergy that is overcome by IL2.
Several observations described above rule out the possibility References that the human 11,2 gene product is a target for an immune response that is responsible for the observed lack of tumorigenicity of the IL2-secreting cells: (a) inhibition of tumor formation by parental CMS-5 cells admixed with IL2-secreting counterparts (Fig . 3) ; (b) induction of protective immune response against unmodified CMS-5 cells in mice that rejected the IL2-producing tumor cells (Table 3) ; and (c) spleen cells from mice injected with unmodified CMS-5 cells killed N2/IL2/CMS5 target cells as well as spleen cells from mice injected with I1,2-producing tumor cells (Fig . 4) .
In conclusion, our data demonstrate that retroviral vectors can be used to introduce the IL2 gene into tumor cells. Depending upon the construct chosen, the resulting persistent expression and secretion of low levels of cytokine are sufficient to have a decisive impact on the host anti-tumor response.
